A look at GlaxoSmithKline
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex. The company classifies its business portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Because it’s a British multinational company, GSK reports its revenue in Great British pounds.
The chart above compares GlaxoSmithKline’s revenues and EPS (earnings per share) since 1Q16 along with estimates for its 1Q18.
Stock price performance
GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.
Analysts expect GSK to return ~1.2% over the next 12 months. Analysts’ recommendations show a 12-month target price of $40.43 on the stock compared to its price of $39.93 on April 6, 2018.
There are five analysts tracking GlaxoSmithKline’s ADR (American depositary receipt). Of these analysts, one recommends a “strong buy,” while four recommend “holds.” There are 25 analysts tracking GlaxoSmithKline stock. Of these, four recommend “strong buys,” six recommend “buys,” 13 recommend “holds,” and two recommend “sells.” The consensus rating for GlaxoSmithKline is 2.52, which represents a strong buy for value investors.
Analysts’ revenue estimates
GlaxoSmithKline’s revenue is mainly driven by its strong operational performance across all three of its business segments, including Pharmaceuticals, Vaccines, and Consumer Healthcare.
Analysts expect GSK to see revenue of 7.3 billion pounds in 1Q18, a 0.9% fall compared to 1Q17. It expects the company to see EPS of 0.26 pence in 1Q18.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!